Steven Novick

2.1k citations

28 papers · 1.4k indexed · 1 hit paper · h-index 16

Co-authors: Steven L. Soignet Stephanie Stahl Beverly S. Mitchell Mary Jo Lehman Roberto Guerciolini Jessica Anderson Thomas C. Shea Julian Adams
Topics: Chronic Lymphocytic Leukemia Research (10 papers)Chronic Myeloid Leukemia Treatments (7 papers)Acute Lymphoblastic Leukemia research (5 papers)
Cited by: Hematology Genetics Oncology
Journals: Journal of Clinical Oncology Blood Oncogene
Partner nations: United States Switzerland Germany

In The Last Decade

Steven Novick

27 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies

2002 586 citations Robert Z. Orlowski, Thomas E. Stinchcombe et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Steven Novick

Since Specialization

Citations

This map shows the geographic impact of Steven Novick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Novick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Novick more than expected).

Fields of papers citing papers by Steven Novick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Novick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Novick. The network helps show where Steven Novick may publish in the future.

Co-authorship network of co-authors of Steven Novick

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Novick. A scholar is included among the top collaborators of Steven Novick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Novick. Steven Novick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 1 study (NCT04931823) of CPO100 (albumin bound docetaxel) in patients with advanced solid tumors. 2024 ·Journal of Clinical Oncology ·Dale R. Shepard,(unknown),(unknown),Patricia LoRusso,Leonard J. Appleman,Alexander I. Spira,Lee S. Rosen,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Christopher Seng Hong Lim,(unknown),(unknown),Steven Novick,(unknown)	1
2	KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma 2020 ·Blood ·Saad Z. Usmani,Jesús G. Berdeja,Anna Truppel-Hartmann,(unknown),(unknown),Suresh G. Shelat,Steven Novick,Nina Shah	19
3	KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma 2020 ·Blood ·Michel Delforge,Rachid Baz,Michèle Cavo,Natalie S. Callander,Armin Ghobadi,Paula Rodríguez‐Otero,María‐Victoria Mateos,Monica Massaro,Li Ding,Payal Patel,Gianfranco Pittari,Steven Novick,Sergio Giralt,Jesús G. Berdeja	17
4	Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study 2015 ·Journal of Cancer Research and Clinical Oncology ·Andreas Hochhaus,Michele Baccarani,Francis J. Giles,Philipp D. le Coutre,Martin Müller,Andreas Reiter,(unknown),Mimi Leung,Steven Novick,Hagop M. Kantarjian	44
5	Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial 2015 ·The Lancet Oncology ·Jean‐Yves Blay,Lin Shen,Yoon‐Koo Kang,Piotr Rutkowski,Shukui Qin,Dmitry Nosov,Desen Wan,Jonathan C. Trent,Vichien Srimuninnimit,Zsuzsanna Pápai,Axel Le Cesne,Steven Novick,(unknown),Shuyuan Mo,Steven Green,Peter Reichardt,George D. Demetri	80
6	Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam 2014 ·The Journal of Clinical Pharmacology ·Hefei Zhang,Jennifer Sheng,(unknown),Cheng Zheng,Wei Zhou,(unknown),(unknown),Steven Novick	15
7	Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study 2013 ·Journal of Cancer Research and Clinical Oncology ·Andreas Hochhaus,Philipp D. le Coutre,Hagop M. Kantarjian,Michele Baccarani,Philipp Erben,Andreas Reiter,Tracey McCulloch,Xiaolin Fan,Steven Novick,Francis J. Giles	7
8	Phase III trial of nilotinib versus imatinib as first-line targeted therapy of advanced gastrointestinal stromal tumors (GIST). 2013 ·Journal of Clinical Oncology ·Jean‐Yves Blay,Lin Shen,Yoon‐Koo Kang,Piotr Rutkowski,Shukui Qin,Dmitry Nosov,Steven Novick,(unknown),Shuyuan Mo,Peter Reichardt,George D. Demetri	9
9	Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study 2012 ·Leukemia ·Francis J. Giles,Philipp D. le Coutre,Javier Pinilla‐Ibarz,Richard A. Larson,Norbert Gattermann,Oliver G. Ottmann,Andreas Hochhaus,Jerald P. Radich,Giuseppe Saglio,Timothy P. Hughes,Giovanni Martinelli,D-W Kim,Steven Novick,Kris Gillis,Xingwen Fan,Jörge E. Cortes,Michele Baccarani,Hagop M. Kantarjian	177
10	Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers 2012 ·Cancer Chemotherapy and Pharmacology ·Ophelia Yin,Véronique Bédoucha,Tracey McCulloch,Cheng Zheng,Wei Zhou,Azra Hussaini,Steven Novick	9
11	Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study, 2011 ·Blood ·Philipp D. le Coutre,Francis J. Giles,Javier Pinilla‐Ibarz,Richard A. Larson,Norbert Gattermann,Oliver G. Ottmann,Andreas Hochhaus,Jerald P. Radich,Giuseppe Saglio,Timothy P. Hughes,Giovanni Martinelli,Dong-Wook Kim,Susan Branford,Martin C. Müller,Yaping Shou,Steven Novick,Xiaolin Fan,Jörge E. Cortes,Michele Baccarani,Hagop M. Kantarjian	10
12	Effect of the addition of oblimersen (Bcl-2 antisense) to fludarabine/cyclophosphamide for relapsed/refractory chronic lymphocytic leukemia (CLL) on survival in patients who achieve CR/nPR: Five-year follow-up from a randomized phase III study 2008 ·Journal of Clinical Oncology ·(unknown),Johnnie N. Moore,Junjie Wu,Steven Novick,Susan O’Brien	15
13	Phase 1 Assessment of an Orally Bioavailable Formulation of Gallium Nitrate (G4544). 2007 ·Blood ·Thomas B. Julian,(unknown),Moses O. Oyewumi,Steven Novick,(unknown),Robert Brown,(unknown),Raymond P. Warrell,(unknown)	1
14	Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity 2005 ·Journal of Clinical Oncology ·Guido Marcucci,Wendy Stock,Guowei Dai,Rebecca B. Klisovic,Shujun Liu,Marko I. Klisovic,William Blum,Cheryl Kefauver,Dorie A. Sher,Margaret Green,Mollie E. Moran,Kati Maharry,Steven Novick,Clara D. Bloomfield,James A. Zwiebel,Richard A. Larson,Michael R. Grever,Kenneth K. Chan,John C. Byrd	112
15	Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia. 2005 ·Blood ·Blanche H. Mavromatis,R. Kanti,Paul K. Wallace,(unknown),(unknown),(unknown),(unknown),Kenneth K. Chan,(unknown),Steven Novick,Asher Chanan‐Khan	5
16	Phase I to II Multicenter Study of Oblimersen Sodium, a Bcl-2 Antisense Oligonucleotide, in Patients With Advanced Chronic Lymphocytic Leukemia 2005 ·Journal of Clinical Oncology ·Susan O’Brien,Charles Cunningham,(unknown),Anna Turkina,Steven Novick,R. Kanti	147
17	Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies 2003 ·Investigational New Drugs ·Robert Wieder,Steven Novick,Bruce W. Hollis,Margarette Bryan,Suzanne Chanel,(unknown),(unknown),Tracie Saunders,Lillian Pliner,Jonathan S. Harrison,Peter L. Bonate,(unknown),Steven L. Soignet	15
18	CYP3A INDUCTION BY N-HYDROXYFORMAMIDE TUMOR NECROSIS FACTOR-α CONVERTING ENZYME/MATRIX METALLOPROTEINASE INHIBITORS: USE OF A PREGNANE X RECEPTOR ACTIVATION ASSAY AND PRIMARY HEPATOCYTE CULTURE FOR ASSESSING INDUCTION POTENTIAL IN HUMANS 2003 ·Drug Metabolism and Disposition ·Timothy K. Tippin,Geraldine A. Hamilton,Linda B. Moore,(unknown),Summer Jolley,Thomas A. Brodie,Robert Andrews,J. David Becherer,Darryl McDougald,Michael D. Gaul,Debie J. Hoivik,(unknown),Jürgen Lehmann,Steven A. Kliewer,Steven Novick,(unknown),Zhiyang Zhao,Edward L. LeCluyse	8
19	Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignanciesbreakdown → 2002 ·Journal of Clinical Oncology ·Robert Z. Orlowski,Thomas E. Stinchcombe,Beverly S. Mitchell,Thomas C. Shea,Albert S. Baldwin,Stephanie Stahl,Julian Adams,Dixie‐Lee Esseltine,Peter J. Elliott,Christine Pien,Roberto Guerciolini,Jessica Anderson,Natalie D. Depcik‐Smith,(unknown),Mary Jo Lehman,Steven Novick,Owen A. O’Connor,Steven L. Soignet	586
20	rsc: a novel oncogene with structural and functional homology with the gene family of exchange factors for Ral 1997 ·Oncogene ·David R. D’Adamo,Steven Novick,(unknown),(unknown),Àngel Pellicer	49

About Steven Novick

Steven Novick is a scholar working on Hematology, Genetics and Gastroenterology, having authored 28 papers that have together received 1.4k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (10 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Acute Lymphoblastic Leukemia research (5 papers). The work is most often cited by research in Hematology (645 citations), Genetics (362 citations) and Oncology (437 citations). Steven Novick has collaborated with scholars based in United States, Switzerland and Germany. Frequent co-authors include Steven L. Soignet, Stephanie Stahl, Beverly S. Mitchell, Mary Jo Lehman, Roberto Guerciolini, Jessica Anderson, Thomas C. Shea, Julian Adams, Thomas E. Stinchcombe and Dixie‐Lee Esseltine. Their work appears in journals such as Journal of Clinical Oncology, Blood and Oncogene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact